STOCK TITAN

Arcus Biosciences, Inc. - RCUS STOCK NEWS

Welcome to our dedicated page for Arcus Biosciences news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Biosciences stock.

Arcus Biosciences, Inc. (NASDAQ: RCUS) is a cutting-edge, clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment. Founded in 2015 by experienced researchers from the biotechnology and pharmaceutical sectors, Arcus is based in the San Francisco Bay Area, a hub for biotechnological innovation.

Arcus Biosciences focuses on leveraging insights in immunology to create new cancer therapeutics. The company is particularly known for its work on the ATP-adenosine pathway, a significant driver of immunosuppression in the tumor microenvironment. Their aim is to optimize small-molecule immuno-oncology product candidates that could revolutionize cancer treatment.

Arcus has a robust product pipeline that includes several promising candidates such as Domvanalimab, Etrumadenant, AB598, and Casdatifan. These drugs target different aspects of the immune system to either modulate cellular processes in cancer or directly combat tumor growth.

Significant achievements include successful clinical trials for treating various types of cancers, including lung, colorectal, and pancreatic cancers. The company operates through a single segment focused on the development and commercialization of its immunotherapies.

Arcus prides itself on maintaining an internal team of highly skilled professionals rather than outsourcing its research and development efforts. This approach ensures the highest quality and innovation in their drug discovery process.

With ongoing partnerships and collaborations, notably with Gilead Sciences, Arcus is well-positioned to bring its innovative therapies to market, providing new hope for patients with cancer.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
none
-
Rhea-AI Summary
Gilead Sciences and Arcus Biosciences announce updated results from the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer. Domvanalimab-containing study arms show a reduction in risk of progression or death compared to zimberelimab monotherapy. Objective response rate also improved in the domvanalimab-containing arms. Results will be presented at the ASCO Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Gilead Sciences and Arcus Biosciences announced updated results from the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer. The study evaluated the combinations of domvanalimab plus zimberelimab and etrumadenant versus zimberelimab monotherapy. The results showed a reduction in the risk of disease progression or death for the domvanalimab-containing arms. Objective response rate also improved in the domvanalimab-containing arms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.63%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.63%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
none

FAQ

What is the current stock price of Arcus Biosciences (RCUS)?

The current stock price of Arcus Biosciences (RCUS) is $15.5 as of December 20, 2024.

What is the market cap of Arcus Biosciences (RCUS)?

The market cap of Arcus Biosciences (RCUS) is approximately 1.4B.

What does Arcus Biosciences, Inc. do?

Arcus Biosciences develops innovative immunotherapies for cancer treatment, focusing on the ATP-adenosine pathway.

Where is Arcus Biosciences located?

The company is based in the San Francisco Bay Area, a major center for biotechnology research.

When was Arcus Biosciences founded?

The company was founded in 2015 by a group of seasoned researchers.

What is the core focus of Arcus Biosciences' research?

Arcus focuses on developing small-molecule immuno-oncology product candidates that work on the ATP-adenosine pathway.

What are some of Arcus Biosciences' main products?

Their product pipeline includes Domvanalimab, Etrumadenant, AB598, and Casdatifan.

What types of cancer does Arcus Biosciences target?

The company conducts clinical trials for various cancers, including lung, colorectal, and pancreatic cancers.

Does Arcus Biosciences outsource its research and development?

No, Arcus prides itself on maintaining an internal team of skilled professionals for its R&D efforts.

With whom does Arcus Biosciences have significant partnerships?

Arcus has ongoing collaborations, notably with Gilead Sciences, to advance its research and bring therapies to market.

What makes Arcus Biosciences unique?

The company combines cutting-edge technology with innovative approaches to drug discovery, focusing on both small molecules and biologics.

What is the mission of Arcus Biosciences?

The mission is to create new cancer therapeutics through emerging insights in immunology, providing new hope for patients.

Arcus Biosciences, Inc.

NYSE:RCUS

RCUS Rankings

RCUS Stock Data

1.41B
54.37M
40.6%
60.08%
8.27%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HAYWARD